Pathogen-reduction systems for blood components: The current position and future trends
Authors:
- Jerard SeghatchianJSJerard Seghatchian
- Gracinda de SousaGSGracinda de Sousa
- 1 December 2006
- journal article
- review article
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 35 (3) , 189-196
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Pathogen inactivation technology: cleansing the blood supplyJournal of Internal Medicine, 2005
- Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2003
- Nanofiltration of plasma‐derived biopharmaceutical productsHaemophilia, 2003
- Current strategies for the provision of safer plasma and its derivatives: an updateTransfusion and Apheresis Science, 2001
- Current strategies on pathogen removal/inactivation: an overview.Transfusion and Apheresis Science, 2001
- A randomized trial of solvent/detergent‐treated and standard fresh‐frozen plasma in the coagulopathy of liver disease and liver transplantationTransfusion, 1999
- Current status of solvent/detergent‐treated frozen plasmaTransfusion, 1998
- Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 1992
- Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible LightVox Sanguinis, 1991
- Inability of solvent‐detergent (S‐D) treated factor VIII concentrate to inactivate parvoviruses and non‐lipid enveloped non‐a, non‐b hepatitis virus in factor VIII concentrate: Advantages to using sterilizing 100°c dry heat treatmentAmerican Journal of Hematology, 1990